NCT06756074 Reinforced Pancreaticojejunostomy With or Without glubran2
| NCT ID | NCT06756074 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Minia University |
| Condition | Pancreatic Fistula |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2026-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2025-01-15 with a primary completion date of 2026-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. To reduce pancreatic fistula, many authors recommend different techniques in pancreatojejunostomy. The purpose of this study is to determine which is the best method in preventing pancreatic fistula by enforce pancreaticojejunostomy with tissue glue .
Eligibility Criteria
Inclusion Criteria: * All the patients undergoing pancreaticoduodenectomy for cancer * Patients able to give their informed consent Exclusion Criteria: * Unfit patients for surgery due to severe medical illness. * Inoperable patients by imaging studies, irresectable tumors after laparotomy or diagnostic laparoscopy. * Presence of distant metastasis . * Patients refused to participate in the study.
Contact & Investigator
Saleh K Saleh, MD
PRINCIPAL INVESTIGATOR
Minia University
Frequently Asked Questions
Who can join the NCT06756074 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Pancreatic Fistula. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06756074 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06756074 currently recruiting?
Yes, NCT06756074 is actively recruiting participants. Contact the research team at salehkhairy@mu.edu.eg for enrollment information.
Where is the NCT06756074 trial being conducted?
This trial is being conducted at Minya, Egypt.
Who is sponsoring the NCT06756074 clinical trial?
NCT06756074 is sponsored by Minia University. The principal investigator is Saleh K Saleh, MD at Minia University. The trial plans to enroll 100 participants.